Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis

NCT06963203 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 486

Last updated 2025-07-02

No results posted yet for this study

Summary

The goal of this observational study is to learn about the potential differences in morbidity of thyroidectomy (removal of the thyroid gland) depending on the preoperative hormonal status. The main question it aims to answer is:

Do patients undergoing thyroidectomy for thyreotoxicosis (thyroid hyperfunction) due to Graves' disease or Amiodarone induced thyreotoxicosis have comparable complication rates depending on their thyroid metabolic status prior or during the procedure.

The data from participants undergoing a thyroidectomy at one of the study sites will be prospectively registered in the EUROCRINE registry, including an add-on module for additional study specific routine data. The operation itself, the preoperative or postoperative treatments are not altered in any way.

Conditions

  • Graves Disease
  • Amiodarone-Induced Thyrotoxicosis
  • Thyroidectomy

Sponsors & Collaborators

  • Spital Männedorf

    collaborator UNKNOWN
  • Spital Limmattal Schlieren

    collaborator OTHER
  • Centre Hospitalier Universitaire Vaudois

    collaborator OTHER
  • Ospedale Regionale di Mendrisio

    collaborator OTHER
  • Kantonsspital St. Gallen, Switzerland

    collaborator UNKNOWN
  • Cantonal Hosptal, Baselland

    collaborator OTHER
  • St. Claraspital AG

    collaborator OTHER
  • University Hospital, Geneva

    collaborator OTHER
  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER
  • ASZ Aalst

    collaborator OTHER
  • University Hospital Virgen de las Nieves

    collaborator OTHER
  • University of Nancy

    collaborator OTHER
  • Hospital Costa del Sol

    collaborator OTHER
  • Evgenidion Hospital Athens, Greece

    collaborator UNKNOWN
  • Andrea Goldmann

    lead OTHER

Principal Investigators

  • Andrea Goldmann, MD · Kantonsspital Winterthur KSW

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • Belgium
  • France
  • Greece
  • Spain
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06963203 on ClinicalTrials.gov